The analysis points out that while the iShares Global Healthcare ETF (IXJ) has performed better over the past five years, the State Street SPDR S&P Biotech ETF (XBI) has outperformed IXJ year-to-date, and over the three- and ten-year periods. XBI's advantage comes from its focus on small-cap stocks, which are experiencing their best year since 1991. 81% of XBI's portfolio consists of small-cap stocks, whereas 81% of IXJ's portfolio is made up of large-cap stocks. XBI's trailing 12-month dividend yield is 0.4%, compared to IXJ's 1.4%.